WINTON GROUP Ltd Acquires 29,124 Shares of Progyny, Inc. (NASDAQ:PGNY)

WINTON GROUP Ltd boosted its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 62.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,515 shares of the company's stock after acquiring an additional 29,124 shares during the quarter. WINTON GROUP Ltd owned 0.09% of Progyny worth $1,303,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in shares of Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after purchasing an additional 1,246 shares during the last quarter. Signaturefd LLC grew its position in shares of Progyny by 1,355.0% in the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after buying an additional 1,355 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock valued at $51,000 after buying an additional 1,526 shares during the period. KBC Group NV raised its position in shares of Progyny by 84.6% during the fourth quarter. KBC Group NV now owns 4,669 shares of the company's stock worth $81,000 after acquiring an additional 2,140 shares during the last quarter. Finally, Entropy Technologies LP lifted its stake in shares of Progyny by 5.5% in the fourth quarter. Entropy Technologies LP now owns 47,883 shares of the company's stock worth $826,000 after acquiring an additional 2,499 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

A number of analysts have weighed in on PGNY shares. BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price for the company in a research report on Monday. Bank of America lifted their target price on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. JPMorgan Chase & Co. boosted their target price on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Finally, Canaccord Genuity Group increased their price target on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, February 28th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $23.64.

Progyny Stock Performance

Progyny stock traded up $0.54 during mid-day trading on Tuesday, reaching $22.88. The stock had a trading volume of 249,098 shares, compared to its average volume of 1,691,670. The firm has a market capitalization of $1.95 billion, a PE ratio of 39.47, a price-to-earnings-growth ratio of 2.39 and a beta of 1.41. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $37.92. The stock's 50-day simple moving average is $22.09 and its 200-day simple moving average is $18.50.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.